Genelux (GNLX) Income from Continuing Operations (2022 - 2026)
Genelux (GNLX) posted quarterly Income from Continuing Operations of 9334000.0 for Q1 2026, down 21.02% year-over-year from 11817652.99 in Q1 2025, and up 38.38% quarter-over-quarter from 15147000.0 in Q4 2025.
Genelux (GNLX) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Genelux's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 9334000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 21.02% year-over-year to 9334000.0; the TTM figure through Mar 2026 stood at 43822000.0 (down 42.33% YoY), while the FY2025 annual figure was 111024000.0, down 21.05% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 9334000.0, up from 15147000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4909000.0 in Q3 2022, with the low at 117160000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 8061000.0 (2025), against an average of 14769000.0.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 208.88% in 2023, then surged 94.26% in 2024.
- Genelux's Income from Continuing Operations stood at 3495000.0 in 2022, then slumped by 93.62% to 6767000.0 in 2023, then plunged by 39.78% to 9459000.0 in 2024, then sank by 60.13% to 15147000.0 in 2025, then soared by 38.38% to 9334000.0 in 2026.
- Business Quant data shows GNLX's Income from Continuing Operations at 9334000.0 in Q1 2026, 15147000.0 in Q4 2025, and 11280000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | -9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.33 Mn |
| Dec 31, 2025 | -15.15 Mn |
| Sep 30, 2025 | -11.28 Mn |
| Jun 30, 2025 | -8.06 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -9.46 Mn |
| Sep 30, 2024 | -6.89 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | -9.50 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -117.16 Mn |
| Mar 31, 2023 | -9.57 Mn |
| Dec 31, 2022 | -3.50 Mn |
| Sep 30, 2022 | 4.91 Mn |